Peripheral CB1 Inhibition: A Novel Approach to Sustainable Weight Loss and Improved Metabolic Health
Time: 9:30 am
day: Conference Day Two
Details:
- Uncover the unique approach to obesity treatment with nimacimab, a first-in-class peripheral CB1 inhibitor, by modulating energy expenditure and fat metabolism, while preserving muscle mass
- Discover the potential of nimacimab to offer a safer, more tolerable weight loss option with a favorable gastrointestinal profile and minimal neuropsychiatric side effects, addressing common concerns associated with current obesity treatments
- Explore the latest clinical developments of nimacimab, including its upcoming Phase 2 study designed to evaluate its efficacy in promoting sustainable weight loss and improving metabolic health, both as a monotherapy and in combination with GLP-1 agonists
